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Background: Peripheral nerve injury (PNI) results in a fundamental reorganization of the translational machinery in
the injured peripheral nerve such that protein synthesis is increased in a manner linked to enhanced mTOR and
ERK activity. We have shown that metformin treatment, which activates adenosine monophosphate-activated
protein kinase (AMPK), reverses tactile allodynia and enhanced translation following PNI. To gain a better
understanding of how PNI changes the proteome of the sciatic nerve and ascertain how metformin treatment may
cause further change, we conducted a range of unbiased proteomic studies followed by biochemical experiments
to confirm key results.
Results: We used multidimensional protein identification technology (MUDPIT) on sciatic nerve samples taken from
rats with sham surgery, spinal nerve ligation (SNL) surgery or SNL + 200 mg/kg metformin treatment. MUDPIT
analysis on these complex samples yielded a wide variety of proteins that were sorted according to their peptide
counts in SNL and SNL + metformin compared to sham. These proteins were then submitted to functional
annotation analysis to identify potential functional networks altered by SNL and SNL + metformin treatment.
Additionally, we used click-chemistry-based labeling and purification of nascently synthesized proteins followed by
MUDPIT to further identify peptides that were synthesized within the injured nerve. With these methods, we
identified apolipoprotein E (ApoE) as a protein profoundly increased by PNI and further increased by PNI and
metformin. This result was confirmed by Western Blot of samples from SNL rats and spared nerve injury (SNI) mice.
Furthermore, we show that 7-day treatment with metformin in naïve mice leads to an increase in ApoE expression
in the sciatic nerve.
Conclusions: These proteomic findings support the hypothesis that PNI leads to a fundamental reorganization of
gene expression within the injured nerve. Our data identify a key association of ApoE with PNI that is regulated by
metformin treatment. We conclude from the known functions of ApoE in the nervous system that ApoE may be an
intrinsic factor linked to nerve regeneration after PNI, an effect that is further enhanced by metformin treatment.* Correspondence: hyassine@usc.edu; tjprice@email.arizona.edu
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Despite advances in our understanding of the pathogen-
esis of neuropathic pain, the clinical treatment of this
disorder remains problematic [1]. Hence, there is an
urgent need for novel treatment approaches targeting
molecular mechanisms of pathology induced by periph-
eral nerve injury (PNI). Injured neurons from mamma-
lian peripheral or invertebrate central nerves retain a
capacity for functional regeneration. This regeneration
process apparently involves a re-organization of the
translational capacity of injured axons [2-4]. The change
in axonal protein synthesis after PNI may be functionally
linked to the development and persistence of neuropathic
pain [5-8]. Using rationale pathway analysis approaches
we have shown along with others that neuropathic pain is
correlated with enhanced mammalian target of rapamycin
complex 1 (mTORC1) [5,7] and extracellular signal regu-
lated protein kinase (ERK) [7] activity and that blocking
these pathways attenuates some sequelae of neuropathic
pain [5-8]. An important piece of evidence linking these
pathways to neuropathic pain is the finding that
pharmacologically stimulating adenosine monophosphate-
activated protein kinase (AMPK), which inhibits signaling
through these pathways [9], leads to a resolution of neuro-
pathic allodynia [7].
While these findings link mTOR and ERK activity in
peripheral neurons following PNI to neuropathic pain,
downstream effectors generated via enhanced translation
in the axonal compartment have not been identified. How-
ever, several previous studies have suggested candidate
genes. First, a proteomic profiling of neuromas generated
by PNI suggested an important role for translation control
pathways in neuroma-generated pain [10]. Second, an
important contributor to neuropathic [11-14] and other
types of pathological pain [15-17], voltage-gated Sodium
channel type 1.8 (Nav1.8) mRNA, localizes to the axonal
compartment. This suggests that this crucial channel can
be translated on-demand in the axons of nociceptors [18].
There is also some evidence that TRPV1 mRNA localizes
to axons [19,20] suggesting it can be synthesized in the
axonal compartment of nociceptors. While the candidate
protein or single pathway approach can be successful, the
anatomical and molecular complexity of the nervous
system suggest that most signaling systems are not likely
to be critically dependent on single pathways. This appears
to be the case in terms of changes in translation control
after nerve injury and is a major part of the underlying
rationale to engage AMPK as a potential treatment for
neuropathic pain [7].
It is also clear that changes in gene expression in cells,
other than neurons, either intrinsic to or invading the
injured peripheral nerve may play a crucial role in
neuropathic pain and/or functional recovery after PNI
[21]. In this regard, a variety of extrinsic cell types havebeen identified [22] and the activation of other, intrinsic
cells has been positively correlated with pain induced by
PNI [23]. While it is clear that changes in translation
regulation occur in the axonal compartment after PNI
[7], it is undoubtedly also true that changes in these
pathways may contribute to neuropathic pain and that
AMPK activation may be physiologically linked to these
pathways in such non-neuronal cells.
To gain a better understanding of how PNI changes
the proteome of the sciatic nerve, including axons,
intrinsic and extrinsic cells, and to ascertain how stimu-
lation of AMPK with metformin treatment may cause
further change, we conducted a range of unbiased
proteomic and bioinformatic studies on the sciatic nerve
of rats with or without PNI including PNI and metfor-
min treatment. Our findings suggest a complex change
in PNS signaling networks associated with nerve injury
and its further modulation via treatment with metfor-
min. Moreover, our results, confirmed with biochemical
studies, demonstrate that apolipoprotein E (ApoE) is
strongly upregulated by PNI and nascently synthesized
in the injured sciatic nerve. Interestingly, ApoE, which
is linked to neuroprotection in neurodegenerative and
traumatic nerve injury, is further increased by metfor-
min treatment suggesting a potential role of ApoE in
functional recovery and/or reduction of neuropathic
pain after PNI. Overall, our results create a framework
for the better understanding of changes in translation
control that occur following nerve injury and their
potential contribution to neuropathic pain and nerve
regeneration.
Results
We first sought an unbiased view of the proteome of the
sciatic nerve following proximal injury to the L5 and L6
spinal nerves using the SNL model in rats. We also inves-
tigated how metformin treatment alters the injured prote-
ome by giving rats I.P. injections of 200 mg/kg metformin
daily for 7 days commencing 14 days following SNL
surgery. Sciatic nerve samples were taken 21 days follow-
ing SNL and analyzed by MUDPIT after pooling samples
from 6 animals per group. A control group received sham
surgery and vehicle treatments, while the SNL group
without metformin also received vehicle injections. With
MUDPIT we identified a total of 295 proteins with assigned
peptides from all samples (Additional file 1: Table S1).
Using these assigned peptides, we subdivided proteins
into groups based on the number of peptides observed
in sham, SNL and SNL + metformin groups for each
protein by MUDPIT analysis. Seventy-eight proteins
were identified where a higher absolute number of pep-
tides were observed in the sciatic nerve compared to
sham animals (Additional file 1: Table S2). One of the
most increased peptides was ApoE (82 injured vs. 0
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absolute number of peptides was lower in the injured sci-
atic nerve than in the sham sciatic nerve (Additional file 1:
Table S3). We also examined proteins that had increased
peptide counts with metformin + SNL compared to SNL
alone. Here we found 66 proteins (Additional file 1: Table
S4), including ApoE (290 metformin + SNL vs. 82 SNL
peptides). Seventy-three proteins showed decreased pep-
tide counts in the metformin + SNL group vs. the SNL
group (Additional file 1: Table S5).
Having identified proteins that were altered by SNL and
SNL + metformin, we sought to identify functional prop-
erties of this dataset. To do this we utilized The Database
for Annotation, Visualization and Integrated Discovery
(DAVID). This allowed us to determine enriched cellular
functions following nerve injury or metformin treatment
combined with nerve injury. Within the total proteomic
dataset, we identified 780 functional annotations in
DAVID from proteins identified from those two groups
(Additional file 2: Table S6). Individual datasets are
shown in Additional file 2: Tables S7 and S8. We then
constructed a graph to visualize this data by protein
number per functional annotation (Additional file 2:
Graph 1). We hypothesized that ApoE, which is a pleio-
tropic protein with a wide range of identified cellular
and physiological functions (functional annotations that
include ApoE as a component are highlighted in red in
Additional file 2: Tables S7 and S8 and the complete list
of 295 functional annotations is found in Additional file
3: Table S9), may reveal novel insight concerning poten-
tial mechanisms of action of metformin because this
protein was strongly increased in SNL rats and further in-
creased by metformin treatment. To test this, we looked
at functional annotations after SNL or SNL + metformin
that included ApoE as a component and looked at the
number of other proteins identified in the proteome from
those samples that matched those annotations. The
complete list is shown in Additional file 3: Table S10 and
is shown graphically in Figures 1 and 2. Interestingly, we
noted several functional annotations related to develop-
ment and repair that were enriched both in the SNL and
SNL + metformin groups. We also noted several func-
tional annotations that were unique to the SNL group
and that were decreased following metformin treatment
with SNL. Interestingly, these functional annotations
were largely related to ionic and other forms of homeo-
stasis that might be compensatory mechanisms related
to the development of ectopic activity in injured nerves
(Figure 2). Crucially, in the SNL + metformin group,
there was a strong enrichment of functional annotations
linked to regeneration, differentiation and repair of the
peripheral nervous system that were unique to this treat-
ment (Figure 2). Hence, using a completely unbiased
proteomic screen and an unbiased functional annotationalgorithm (DAVID), we have identified an enrichment of
functional annotations linked to nerve injury induced
regeneration and repair induced by metformin based on
the identification of ApoE as a protein strongly induced by
nerve injury and further increased by metformin. These
functional annotations include “axon regeneration in the
peripheral nervous system”, “axonogenesis”, “axon regen-
eration” and “response to axon injury” (Figure 2). These
functional annotations also tended to include microtubule
associated protein 1B (IPI00372009) and neurofilament
light polypeptide (IPI00231302).
We then utilized click-chemistry-based labeling and
purification of nascently synthesized proteins followed
by MUDPIT to further identify peptides that were
nascently synthesized within the injured nerve. This was
done using an ex-vivo approach as detailed in methods.
With this unbiased method, we identified 14 proteins,
including ApoE (Additional file 4: Table S11). Hence, we
show that in addition to being increased by SNL and
further increased by metformin treatment, ApoE is
nascently synthesized in the injured sciatic nerve
(2 peptides in SNL vs. 0 in sham).
Next, we confirmed our MUDPIT findings with ApoE
using Western blot. Comparing ipsilateral to contralat-
eral sciatic nerves from rats 21 days post SNL showed a
clear, robust increase in ApoE expression in the sciatic
nerve (Figure 3A) as has been shown previously with
sciatic nerve crush injury [24]. Furthermore, there is
also a robust increase in ApoE expression in the sciatic
nerves of mice 21 days after SNI surgery, which suggests
that this change occurs across models and across
species (Figure 3B). Our proteomic findings also suggest
that ApoE is increased in the sciatic nerve after PNI. To
assess whether this occurs as a result of metformin
treatment in multiple species we treated naïve mice for
7 days with 200 mg/kg metformin and assessed ApoE
expression in the sciatic nerve. Metformin treatment led
to a doubling of ApoE levels in the sciatic nerve
(Figure 3C). Hence, metformin is a legitimate inducer of
ApoE expression in the PNS in vivo.
Discussion
The objective of this study was to obtain an unbiased
overview of how PNI changes the proteome and func-
tional annotation network of the sciatic nerve and how
these changes are further modified by metformin treat-
ment. Here, we report an overview based on MUDPIT
and DAVID technology of how pathways are altered in
the sciatic nerve distal to PNI and how these pathways
are further modified by treatment with metformin.
Using this technology, we identified ApoE as a protein
profoundly increased and nascently synthesized in the
distal sciatic nerve following PNI in rats and mice.
Moreover, our results from DAVID analysis reveal that
Figure 1 Functional annotation data derived from DAVID algorithm (Part One). Graph derived from the functional annotation chart that
shows all cellular functions that include ApoE as a component (ApoE is assigned to that functional annotation) given as the number of proteins
identified by MUDPIT with that specified functional annotation. The numbers indicate the number of proteins detected in the proteomic study
that are clustered in that functional annotation (all of which include ApoE) following SNL (blue) or SNL with metformin (red) treatment. The
graph includes functional annotations where the protein number in injured sciatic nerves (blue) and in injured nerves following metformin
treatment (red) is not different. Hence, these functional annotations are not modulated by metformin and appear to be associated with an injury
response that is resistant to metformin treatment.
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tions linked either positively or negatively to metformin
treatment that may play a key role in peripheral nerve
regeneration and repair or neuronal excitability, respect-
ively. Our results clearly link metformin treatment to fur-
ther increases in ApoE following PNI and increased
expression of ApoE in sciatic nerves of naïve mice. Hence,
we conclude that although ApoE has long been linked to
PNI, this molecule is a potential regulator of neuropathic
pain and/or regeneration following PNI.
Traditional proteomics methodologies separate com-
plex protein samples by isoelectric point and molecular
weight in 2-dimensional gels. Patterns are compared
between samples by isolating individual protein spots,
followed by proteolytic digestion, and analyzing the
mass of each peptide by Matrix-assisted laser desorption/
ionization-time of flight (MALDI-TOF) mass spectrom-
etry. The measured peptide masses are searched againstthe predicted mass values for theoretical digestion of pro-
teins in a sequence database, and the protein is identified
by a statistically significant number of matches. MUDPIT,
which we have utilized here, eliminates gel separations.
Instead, biochemical fractions containing many proteins
are directly proteolyzed and the enormous number of
peptides generated, are separated by 2-dimensional liquid
chromatography (repeated cycles of fractionation that ex-
tend for 22 hours) before entering the mass spectrometer.
Instead of MALDI-TOF, the procedure employs tandem
mass spectrometry (MS-MS) so that, after the mass of a
peptide is measured, the peptide is fragmented using a
collision-induced dissociation cell and the masses of the
fragmentation products are determined. Using compu-
tational analysis, the data is transformed into an amino
acid sequence. Although one peptide is often sufficient
to identify a protein using this very sensitive technique,
the specificity of this approach improves with increased
Figure 2 Functional annotation data derived from DAVID algorithm (Part Two). Graph derived from the functional annotation chart that
shows all cellular functions that include ApoE as a component (ApoE is assigned to that functional annotation) given as the number of proteins
identified by MUDPIT with that specified functional annotation. The numbers indicate the number of proteins detected in the proteomic study
that are clustered in that functional annotation (all of which include ApoE) following SNL (blue) or SNL with metformin (red) treatment. The
graph indicates number of proteins for functional annotations containing ApoE that are unique to injured nerves (blue) and are not apparent
with metformin treatment (lack of red bars). Moreover, metformin treatment induces the expression of number of proteins that belong to
functional annotations containing ApoE that are not observed with nerve injury. These functional annotations are linked to enhance regeneration
and repair of the peripheral nervous system (red) and these functional annotation sets are absent in SNL rats (lack of blue bars).
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advantage of this approach is the identification of minor
proteins in a biological fraction that cannot be visual-
ized on 2-dimensional gels. Recent studies have identi-
fied 1,000 to 2,000 proteins in a single fraction with
MUDPIT [25].
ApoE is a 34 kDa glycoprotein and is a major deter-
minant of lipid transport and metabolism [24]. ApoE is
strongly up-regulated after sciatic nerve crush injury
where it increases several hundred fold [24] and then
declines once regeneration is complete [26]. In this
model, it has been proposed that macrophages migrat-
ing into the injured site synthesize ApoE, which is then
released concurrently with cholesterol and lipidsderived from the degenerating myelin as ApoE lipopro-
teins. ApoE is then taken up by low-density lipoprotein
(LDL) receptors on the surface of Schwann cells [27] for
recycling and regeneration. However, further studies
reveal an important role for ApoE in neuroregeneration
and remyelination [24,28,29] suggesting a direct effect
of ApoE on neuronal function and, possibly, regener-
ation. ApoE, for example, is well known as an important
mediator of Alzheimer’s disease [30]. ApoE has also
emerged as an important regulator of nerve sprouting
and nerve regeneration as well as neuroprotection.
Several studies have indicated that the addition of ApoE
to cultured neurons enhances nerve sprouting [28,31],
including enhanced sprouting of dorsal root ganglion
Figure 3 ApoE expression is increased in the sciatic nerve following PNI and is induced by metformin. A) Rat sciatic nerves (n = 6) were
taken 21 days following SNL surgery and ApoE was assessed by Western blot. B) Mouse sciatic nerves (n = 6) were taken 21 days following SNI
surgery and ApoE was assessed by Western blot. C) Mice were treated for 7 days with 200 mg/kg metformin and sciatic nerves were removed
and assessed for ApoE expression (n = 6). βIII tubulin was used as a loading control in all studies. ** p < 0.01, *** p < 0.001.
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depletion of ApoE leads to worse outcomes [32-34],
whereas enhancing ApoE activity is beneficial [35-40].
More recently, an ApoE mimetic, COG112, was shown
to significantly improve recovery of motor and sensory
function following sciatic nerve crush in C57BL/6 mice
[29]. This indicates a positive modulatory role of ApoE
in nerve regeneration. This finding also suggests that
further enhancing ApoE expression or action in addition
to increases that occur from injury alone are beneficial.
This suggests that enhancements observed with metfor-
min may be important in functional recovery after nerve
injury. While this hypothesis requires further testing, it is
very strongly supported by functional annotation analysis.
Finally, ApoE has potent anti-inflammatory properties.Mice lacking ApoE have a substantially exaggerated
response to LPS with regard to tumor necrosis factor α
(TNFα), interleukin-6 (IL-6), (IL-12) and interferon
gamma (IFNγ) [41]. Reconstitution of plasma levels of
ApoE in ApoE-knockout mice normalizes LPS-induced
IL-12 and significantly reduces LPS-induced TNFα plasma
levels. Sustained chronic inflammation is known to be
detrimental for functional recovery following PNI [42].
PNI and neuropathic pain are associated with changes in
proinflammatory cytokine expression in the PNS, where
these factors may play a direct role in sensitizing injured
sensory afferents [43]. Thus, stimulating endogenous
expression of ApoE, as can be done with metformin ad-
ministration, may provide benefits by repairing damaged
nerves and modulating pain. This effect of metformin may
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ologies where ApoE might either be deficient or play a
beneficial role therapeutically.
There is strong evidence that changes in translation
regulation may underlie pathology leading to and
maintaining neuropathic pain [5-8,44]. PNI induces a
complete reorganization of translational machinery in
the PNS [7]. This change is functionally linked to
altered sensory processing, mainly allodynia [7] and
pin-prick hyperalgesia [5,6], as revealed by behavioral
pharmacology studies. One possible drawback of utiliz-
ing pharmacological mechanisms to block translation
regulation pathways for the treatment of neuropathic
pain is a detrimental effect on nerve regeneration due to
the key role that translation regulation pathways play in
this event, at least in vitro [45]. We argue that activating
AMPK to achieve regulation of enhanced translation
following nerve injury is unlikely to create these adverse
consequences. Again, findings using the DAVID algo-
rithm very strongly support this conclusion as they
show that metformin-induced increases in ApoE are
linked to functional annotations that are predicted to
enhance peripheral nerve regeneration and repair. Here
several key findings should be considered: 1) while
metformin treatment blocks dysregulated translation
after PNI, it does not reduce normal translation [7],
2) profiling of the effects of metformin on the translatome
reveals that metformin targets only a subset of mRNAs to
alter the proteome [46] (consistent with our findings here)
and 3) metformin increases ApoE expression which is
linked to enhanced functional recovery after PNI. In that
regard, it is critical to note that while ApoE participates in
a wide range of cellular functions, after metformin treat-
ment, the shift in the proteome changes the context of
overall cellular functions such that a set of functional an-
notations (Figure 2, red bars) containing ApoE and highly
enriched in regeneration and repair is revealed. Moreover,
metformin treatment reduced functional annotations
linked to neuronal excitability induced by SNL (Figure 2,
blue bars) consistent with its effect on reducing neuro-
pathic allodynia in rats in this model of neuropathic pain
[7]. While we cannot rule out other possible mechanisms,
with the exception of AMPK, for these effects of metfor-
min, the safety, clinical availability and tolerability of this
drug make it an attractive candidate for human trials for
the treatment of neuropathic and possibly other forms of
pain [7,47].
Materials and methods
Surgery and behavioral testing
Male Sprague Dawley rats (Harlan, 250–300 g) and male
ICR mice (Harlan, 18–22 g) were used. All animal
procedures were approved by the Institutional Animal
Care and Use Committee of The University of Arizonaand were in accordance with International Association
for the Study of Pain guidelines. Prior to surgery all ani-
mals were assessed for mechanical withdrawal thresholds
[48]. Spinal nerve ligation (SNL) was done on rats by tight
ligation of the L5 and L6 spinal nerves as described by
Kim and Chung [49]. Sham control animals underwent
the same surgery and handling as the experimental
animals but without SNL. Spared nerve injury (SNI) was
performed on the mice as described previously [50]. All
animals were allowed to recover for 14 days and all testing
commenced 14 days post-surgery. Following nerve injury,
only animals that developed paw withdrawal thresholds
less than 4.7 g for SNL by day 14 were used. Animals were
placed in acrylic boxes with wire mesh floors and allowed
to habituate for 1 hr. Pre-drug mechanical thresholds were
recorded and the animals received intraperitoneal injec-
tions of vehicle or metformin (200 mg/kg) [51]. Naïve
mice received the same dose of metformin via IP injection.
Calibrated von Frey filaments (Stoelting, Wood Dale, IL)
were used for mechanical stimulation of the plantar sur-
face of the left hindpaw and withdrawal thresholds were
calculated using the up-down method [48]. For Western
blotting and proteomic experiments sciatic nerves were
harvested on day 21 after PNI.
Western blotting
Protein was extracted from tissue in lysis buffer (50 mM
Tris HCl, 1% Triton X-100, 150 mM NaCl, and 1 mM
EDTA at pH 7.4) containing protease and phosphatase
inhibitor mixtures (Sigma) with an ultrasonicator on ice,
and cleared of cellular debris and nuclei by centrifugation
at 14,000 RCF for 15 min at 4°C. Fifteen micrograms of
protein per well were loaded and separated by standard
7.5% or 10% SDS-PAGE. Proteins were transferred to
Immobilon-P membranes (Millipore) and then blocked
with 5% dry milk for 3 h at room temperature. The blots
were incubated with primary antibody overnight at 4°C
and detected the following day with donkey anti-rabbit
antibody conjugated to horseradish peroxidase (Jackson
Immunoresearch). Signal was detected by ECL on chemi-
luminescent films. ApoE was normalized to the expression
GAPDH and/or βIII tubulin on the same membrane.
Membranes were stripped prior to antibody incubation for
normalization. Densitometric analyses were performed
with Image J software (NIH). ApoE antibody was from
AbCam (ab20874) and used at a 1:2500 dilution.
Nascent protein synthesis in sciatic nerves
Ipsilateral and contralateral sciatic nerves from SNL rats
or ipsilateral sciatic nerves from sham rats were excised at
a length of 2 cm. The nerves were then cut to a length of
1 cm and incubated in DMEM/F12 supplemented with
50 μM of Azidohomoalanine (AHA). After 2 hours of
incubation at 37°C in a humidified 95% air/5% CO2
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ultrasonication in lysis buffer. AHA incorporating proteins
were immobilized on alkyne conjugated agarose resin
using Click-iT Protein Enrichment Kit (Invitrogen, Cat #
C10416). The click chemistry reaction results in a covalent
bond between the azide (AHA) containing nascently
synthesized protein and the alkyne conjugated agarose
resin which allowed us to eliminate proteins that are not
nascently synthesized. The agarose resin conjugated with
the nascent proteins was then subjected to trypsin diges-
tion generating the peptides that underwent proteomic
analysis.
Proteomics
We analyzed three samples, each containing 1 microgram
of protein pooled from each group (control, injured and
metformin) treated by multidimensional protein identifi-
cation technology (MUDPIT). For these complex protein
samples, which were initially prepared in standard West-
ern blot lysis buffer, homogenized and cleared of nuclei
and cellular debris by centrifugation as described above,
ammonium bicarbonate was added to a concentration of
0.1 M; 40 μL of 10 mM DTT was then added before redu-
cing at 56°C for 45 min. Reduced cysteines were alkylated
by addition of 40 μL of 55 mM iodoacetamide (10 mM
final concentration) and incubated for 30 min at room
temperature. Proteolysis was initiated with a 1:25 ratio (by
weight) of sequencing grade modified trypsin and allowed
to proceed overnight at 37°C. The digest was stored at
−20°C until analysis. For MUDPIT, we used a microbore
HPLC system (Paradigm MS4; Michrom, Auburn, CA)
with two separate strong cation exchange and reversed
phase columns: a 100 μm I.D. capillary packed with 7 cm
of 5 μm Vydac C18 reversed phase resin and a separate
250 μm I.D. capillary packed with 7 cm of 5 μm
Partisphere strong cation exchanger resin (Whatman,
Clifton, NJ). The sample (4.36 μg) was acidified using
trifluoroacetic acid (TFA) and manually injected onto
the strong cation exchange column, the effluent from
the column being fed through reversed phase column.
A representative 12-step MUDPIT analysis includes the
following solutions: 10% methanol/0.1% formic acid,
0.01% TFA (buffer A); 95% methanol/0.1% formic acid,
0.01% TFA (buffer B); 10% methanol/0.1% formic acid,
0.01% TFA (buffer C); and 500 mM ammonium acetate/
10% methanol/0.1% formic acid, 0.01% TFA (buffer D).
Step 1 consisted of a 5-min equilibration step at 100%
buffer A, another equilibration step for 5 min at 25%
buffer B (75% buffer A), and a 40 min gradient from
25% buffer B to 65% buffer B, followed by 10 min 65%
buffer B and 10 min 100% buffer A. Chromatography
steps 2–12 followed the same pattern: 15 min of the
appropriate percentage of buffers C and D followed by a
2-min 100% buffer C wash, a 5-min wash with 100%buffer A, equilibration with 25% buffer B for 5 min, a
gradient from 25% buffer B to 65% buffer B in 40 min;
and finally a 10-min 65% buffer B wash and a 10-min
100% buffer A wash. The buffer C/buffer D percentages
used were 95/5%, 90/10%, 85/15%, 80/20%, 70/30%,
60/40%, 40/60%, 20/80%, 0/100%, 0/100%, and 0/100%
for the 11 salt steps. MS/MS and database searching
conditions were the same as those described previously
[52]. We used scaffold to filter the results according to
previous criteria for reliable sequence peptides [53,54].
In scaffold, proteins were identified first by noting
assigned peptides for a given protein (sequence match).
The number of peptides identified for a given protein
were then totaled for all identified proteins. Hence,
“assigned peptides” refers to peptides that match a
protein based on sequence matching and “number of
peptides” refers to the total number of peptides for a
given protein identified through MUDPIT. Proteins
were assigned to categories for analysis based on the
number of peptides identified for the protein according
to treatment.
Gene ontology and functional annotation analysis
We utilized The Database for Annotation, Visualization
and Integrated Discovery (DAVID, http://david.abcc.
ncifcrf.gov, [55,56]) in order to determine enriched cellular
functions following nerve injury or treatment with metfor-
min. The Accession numbers of the list of proteins with at
least 1 assigned spectrum from sciatic nerves taken from
SNL or SNL+metformin treated rats were submitted as
gene list to DAVID. The list of proteins with at least 1
assigned spectrum from uninjured nerve served as the
background list. The Functional Annotation Chart was
generated using the default annotation categories. The
Functional Annotation of ApoE was extracted from the
Functional Annotation Table. The data was exported from
DAVID and further organized using Microsoft Excel.
Additional files
Additional file 1: Table S1. List of all proteins found in the sciatic
nerve by MUDPIT with the number of peptides found in SNL, sham and
SNL + metformin listed for each protein. ApoE is in red. Table S2. List of
all proteins increased by SNL treatment compared to sham animals.
Table S3. List of all proteins decreased by SNL compared to sham. Table
S4. List of all proteins increased by SNL + metformin. Table S5. List of all
proteins decreased by SNL + metformin.
Additional file 2: Table S6. List of all GO terms identified in SNL
(injured) and SNL + Metformin (Metformin) organized by the number of
proteins found per GO term for each treatment. Graph 1. The graph
shows all the data in Table S6 in graphical form organized by number of
proteins per GO term. Table S7. All GO terms found in SNL rats with GO
terms that contain ApoE shown in red. Table S8. All GO terms found in
SNL + Metformin rats with GO terms that contain ApoE shown in red.
Additional file 3: Table S9. List of all GO terms found in SNL or SNL +
Metformin rat sciatic nerves that contain ApoE. Table S10. List of all GO
terms containing ApoE by number of proteins found in SNL (injured)
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http://www.molecularpain.com/content/9/1/14versus SNL + Metformin (Metformin). Figure 1 and 2. Graphs show Table
10 data in graphical form.
Additional file 4: Table S11. Proteins identified from SNL (injured) or
sham (control) sciatic nerves that were nascently synthesized, defined by
incorporation of AHA. Peptide numbers per protein are listed. ApoE is in
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